MedWatch

Novo Nordisk CEO's pay sets itself apart on especially one point

German investment bank Berenberg has compared the salaries of a range of top execs in the pharmaceutical industry, and in opposition to everyone else, Lars Fruergaard Jørgensen's bonus scheme is not tied to the company share price.

Novo Nordisk President & CEO | Photo: Stine Bidstrup/ERH

The bonus scheme of Novo Nordisk CEO and President Lars Fruergaard Jørgensen is not tied in with the share price of the Danish pharmaceutical company, which comes as a surprise to German investment bank Berenberg.

The bank has analyzed the salaries of CEOs in 12 of the world's largest pharmaceutical companies, and Fruergaard Jørgensen's bonus scheme is the only one that does not correlate with the development of the share price of his company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Latest news

See all jobs